Trial Profile
Neoadjuvant Afatinib Based Treatment Strategies Followed by Surgery in Squamous Cell Carcinoma of the Head and Neck: an EORTC NOCI-HNCG Window Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Afatinib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- 15 Jan 2018 Results published in the Annals of Oncology
- 06 Jul 2016 Status changed from active, no longer recruiting to completed.
- 16 Jun 2016 This trial is completed in Italy ( end date: 28 Apr 2016).